Search research articles
Contact Us
Filters
Showing results (831-840 of 866) with videos related to
Page
of 87
Sort By:
Nature
|
November 10, 2025
A fault-tolerant neutral-atom architecture for universal quantum computation
Dolev Bluvstein, Alexandra A Geim, Sophie H Li, et al.
Proteins
|
October 20, 2025
Modeling Protein-Protein and Protein-Ligand Interactions by the ClusPro Team in CASP16
Ryota Ashizawa, Sergei Kotelnikov, Omeir Khan, et al.
Alimentary Pharmacology & Therapeutics
|
July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
Matthew Bohm, Ronghui Xu, Yiran Zhang, et al.
Journal of Medicinal Chemistry
|
June 23, 2007
In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists
Richard J Perner, Stanley DiDomenico, John R Koenig, et al.
The Journal of Clinical Investigation
|
December 15, 2020
Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates
Jim Boonyaratanakornkit, Chihiro Morishima, Stacy Selke, et al.
Inflammatory Bowel Diseases
|
May 6, 2022
Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International Study
Gassan Kassim, Clara Yzet, Nilendra Nair, et al.
Inflammatory Bowel Diseases
|
May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
Eugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Nature
|
July 14, 2025
Experimental demonstration of logical magic state distillation
Pedro Sales Rodriguez, John M Robinson, Paul Niklas Jepsen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis
David M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Joseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Page
of 87
Search research articles
Search
Showing results (831-840 of 866) with videos related to
Sort By:
Page
of 87
Nature
|
November 10, 2025
A fault-tolerant neutral-atom architecture for universal quantum computation
Dolev Bluvstein, Alexandra A Geim, Sophie H Li, et al.
Proteins
|
October 20, 2025
Modeling Protein-Protein and Protein-Ligand Interactions by the ClusPro Team in CASP16
Ryota Ashizawa, Sergei Kotelnikov, Omeir Khan, et al.
Alimentary Pharmacology & Therapeutics
|
July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
Matthew Bohm, Ronghui Xu, Yiran Zhang, et al.
Journal of Medicinal Chemistry
|
June 23, 2007
In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists
Richard J Perner, Stanley DiDomenico, John R Koenig, et al.
The Journal of Clinical Investigation
|
December 15, 2020
Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates
Jim Boonyaratanakornkit, Chihiro Morishima, Stacy Selke, et al.
Inflammatory Bowel Diseases
|
May 6, 2022
Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International Study
Gassan Kassim, Clara Yzet, Nilendra Nair, et al.
Inflammatory Bowel Diseases
|
May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
Eugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Nature
|
July 14, 2025
Experimental demonstration of logical magic state distillation
Pedro Sales Rodriguez, John M Robinson, Paul Niklas Jepsen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis
David M Faleck, Adam Winters, Shreya Chablaney, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Joseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Page
of 87